InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa
Vancouver, British Columbia--(Newsfile Corp. - March 28, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced it has concluded enrollment of its Phase 2 clinical trial using investigational drug INM-755 cannabinol ("CBN") cream for the treatment of patients with epidermolysis bullosa ("EB"), a rare genetic skin disease. The Phase 2 study,...
2023-03-28 7:30 AM EDT
InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions
Vancouver, British Columbia--(Newsfile Corp. - March 13, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced that a peer-reviewed scientific study entitled "Rare phytocannabinoids exert anti-inflamma
2023-03-13 7:30 AM EDT
InMed to Participate in Upcoming Investor Events
Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced the Company's executive team will be participating in the upcoming virtual investor events throughout March 2023: Emerging Growth Conference Date: March 8, 2022 Time: 12:30 PM ET Registration:...
2023-03-06 6:00 PM EST